Anaptysbio (ANAB) Retained Earnings (2016 - 2026)
Anaptysbio's (ANAB) quarterly Retained Earnings came in at -$146000.0 in Q1 2026, up 99.98% YoY from -$73006.7 in Q1 2025, and down 508.33% on a QoQ basis from -$24000.0 in Q4 2025.
Anaptysbio (ANAB) Retained Earnings (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Retained Earnings data on file, last reported at -$146000.0 in Q1 2026.
- Quarterly Retained Earnings rose 99.98% year-over-year to -$146000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$146000.0 (up 99.98% YoY) and the FY2025 annual result came in at -$24000.0, up 100.0% from the prior year.
- Retained Earnings fell to -$146000.0 in Q1 2026, from -$24000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $715.0 million in Q2 2024 to a low of -$822.2 million in Q3 2025.
- A 5-year average of -$52.2 million and a median of -$2.4 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings surged 353931.0% — and 2024, when it tumbled 31284.81%.
- Tracing ANAB's Retained Earnings over 5 years: stood at -$5.2 million in 2022, then soared by 13500.1% to $703.0 million in 2023, then sank by 208.02% to -$759.3 million in 2024, then jumped by 100.0% to -$24000.0 in 2025, then tumbled by 508.33% to -$146000.0 in 2026.
- The last three Retained Earnings figures came in at -$146000.0 (Q1 2026), -$24000.0 (Q4 2025), and -$822.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | -146,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -146,000.00 |
| Dec 31, 2025 | -24,000.00 |
| Sep 30, 2025 | -822.17 Mn |
| Jun 30, 2025 | -6,000.00 |
| Mar 31, 2025 | -798.66 Mn |
| Dec 31, 2024 | -759.33 Mn |
| Sep 30, 2024 | -737.54 Mn |
| Jun 30, 2024 | 714.96 Mn |
| Mar 31, 2024 | 706.41 Mn |
| Dec 31, 2023 | 702.97 Mn |
| Sep 30, 2023 | -2.35 Mn |
| Jun 30, 2023 | -534.58 Mn |
| Mar 31, 2023 | 689.07 Mn |
| Dec 31, 2022 | -5.25 Mn |
| Sep 30, 2022 | 707.66 Mn |
| Jun 30, 2022 | -390.56 Mn |
| Mar 31, 2022 | -358.01 Mn |
| Dec 31, 2021 | -422,000.00 |
| Sep 30, 2021 | -200,000.00 |
| Jun 30, 2021 | -282.55 Mn |